Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of the recent FDA advisory committee discussion on the risks and benefits of HRT, on (a) product labelling and (b) patient information; and whether the MHRA plans to conduct a similar review in the UK.

The Medicines and Healthcare Products Regulatory Agency (MHRA) is an executive agency of the Department which regulates medicine, medical devices, and blood components for transfusion in the United Kingdom, with responsibility for ensuring that medicines meet appropriate standards of safety, quality, and efficacy.

Patient safety is our top priority. The MHRA keeps the safety and effectiveness of all medicines under continuous review, drawing on the latest scientific and clinical evidence.

Hormone replacement therapy (HRT) is an important treatment that helps many women manage menopause symptoms. We continually review emerging data on HRT to ensure that information and guidance in the UK reflects the latest evidence. The MHRA is currently reviewing the available evidence on HRT risks and considering whether updates to the product information are warranted for certain HRT products. This review remains ongoing, and we are currently determining the appropriate next steps based on the evidence.

Women should not make any changes to their treatment plan without first speaking to their general practitioner or healthcare professional, who can provide advice tailored to their individual circumstances.